These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 11600400)
1. In vitro susceptibility of Coxiella burnetii to linezolid in comparison with its susceptibilities to quinolones, doxycycline, and clarithromycin. Gikas A; Spyridaki I; Scoulica E; Psaroulaki A; Tselentis Y Antimicrob Agents Chemother; 2001 Nov; 45(11):3276-8. PubMed ID: 11600400 [TBL] [Abstract][Full Text] [Related]
2. In vitro susceptibility of Coxiella burnetii to trovafloxacin in comparison with susceptibilities to pefloxacin, ciprofloxacin, ofloxacin, doxycycline, and clarithromycin. Gikas A; Spyridaki I; Psaroulaki A; Kofterithis D; Tselentis Y Antimicrob Agents Chemother; 1998 Oct; 42(10):2747-8. PubMed ID: 9756789 [TBL] [Abstract][Full Text] [Related]
3. Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. Spyridaki I; Psaroulaki A; Vranakis I; Tselentis Y; Gikas A Antimicrob Agents Chemother; 2009 Jun; 53(6):2690-2. PubMed ID: 19332671 [TBL] [Abstract][Full Text] [Related]
4. In vitro susceptibility of Coxiella burnetii to azithromycin, doxycycline, ciprofloxacin and a range of newer fluoroquinolones. Lever MS; Bewley KR; Dowsett B; Lloyd G Int J Antimicrob Agents; 2004 Aug; 24(2):194-6. PubMed ID: 15288324 [No Abstract] [Full Text] [Related]
5. Bacteriostatic and bactericidal activities of moxifloxacin against Coxiella burnetii. Rolain JM; Maurin M; Raoult D Antimicrob Agents Chemother; 2001 Jan; 45(1):301-2. PubMed ID: 11120982 [TBL] [Abstract][Full Text] [Related]
6. Activity of telithromycin against thirteen new isolates of C. burnetii including three resistant to doxycycline. Rolain JM; Lambert F; Raoult D Ann N Y Acad Sci; 2005 Dec; 1063():252-6. PubMed ID: 16481522 [TBL] [Abstract][Full Text] [Related]
7. In vitro susceptibilities of spotted fever group rickettsiae and Coxiella burnetti to clarithromycin. Maurin M; Raoult D Antimicrob Agents Chemother; 1993 Dec; 37(12):2633-7. PubMed ID: 8109928 [TBL] [Abstract][Full Text] [Related]
8. [Drug sensitivity analysis of Mycobacterium chelonae and Mycobacterium abscessus and evaluation of Etest for susceptibility testing]. Gui J; Wang F; Hong CY; Li JL; Liang J Zhonghua Jie He He Hu Xi Za Zhi; 2013 Aug; 36(8):567-71. PubMed ID: 24252731 [TBL] [Abstract][Full Text] [Related]
9. In vitro susceptibility to tetracycline and fluoroquinolones of Japanese isolates of Coxiella burnetii. Andoh M; Naganawa T; Yamaguchi T; Fukushi H; Hirai K Microbiol Immunol; 2004; 48(9):661-4. PubMed ID: 15383702 [TBL] [Abstract][Full Text] [Related]
10. Correlation between ratio of serum doxycycline concentration to MIC and rapid decline of antibody levels during treatment of Q fever endocarditis. Rolain JM; Boulos A; Mallet MN; Raoult D Antimicrob Agents Chemother; 2005 Jul; 49(7):2673-6. PubMed ID: 15980335 [TBL] [Abstract][Full Text] [Related]
11. Susceptibility of Rickettsia conorii, R. rickettsii, and Coxiella burnetii to PD 127,391, PD 131,628, pefloxacin, ofloxacin, and ciprofloxacin. Jabarit-Aldighieri N; Torres H; Raoult D Antimicrob Agents Chemother; 1992 Nov; 36(11):2529-32. PubMed ID: 1336950 [TBL] [Abstract][Full Text] [Related]
12. Antibiotic susceptibilities of two Coxiella burnetii isolates implicated in distinct clinical syndromes. Yeaman MR; Roman MJ; Baca OG Antimicrob Agents Chemother; 1989 Jul; 33(7):1052-7. PubMed ID: 2782856 [TBL] [Abstract][Full Text] [Related]
13. In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii. Guna R; Muñoz C; Domínguez V; García-García A; Gálvez J; de Julián-Ortiz JV; Borrás R J Antimicrob Chemother; 2005 Jun; 55(6):950-3. PubMed ID: 15824090 [TBL] [Abstract][Full Text] [Related]
14. Hydroxychloroquine susceptibility determination of Coxiella burnetii in human embryonic lung (HEL) fibroblast cells. Angelakis E; Khalil JB; Le Bideau M; Perreal C; La Scola B; Raoult D Int J Antimicrob Agents; 2017 Jul; 50(1):106-109. PubMed ID: 28478211 [TBL] [Abstract][Full Text] [Related]
15. New insights into the in vitro susceptibility of Pythium insidiosum. Loreto ES; Tondolo JS; Pilotto MB; Alves SH; Santurio JM Antimicrob Agents Chemother; 2014 Dec; 58(12):7534-7. PubMed ID: 25223997 [TBL] [Abstract][Full Text] [Related]
16. The in-vitro anti-rickettsial activity of macrolides. Keysary A; Itzhaki A; Rubinstein E; Oron C; Keren G J Antimicrob Chemother; 1996 Oct; 38(4):727-31. PubMed ID: 8937968 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of rifapentine and other rifamycins against Miller HK; Kersh GJ Microbiol Spectr; 2024 Jul; 12(7):e0103424. PubMed ID: 38864598 [TBL] [Abstract][Full Text] [Related]
18. Susceptibilities of Mycobacterium marinum to gatifloxacin, gemifloxacin, levofloxacin, linezolid, moxifloxacin, telithromycin, and quinupristin-dalfopristin (Synercid) compared to its susceptibilities to reference macrolides and quinolones. Bråbäck M; Riesbeck K; Forsgren A Antimicrob Agents Chemother; 2002 Apr; 46(4):1114-6. PubMed ID: 11897601 [TBL] [Abstract][Full Text] [Related]
19. The inhibitory effect of fluoroquinolones on Coxiella burnetii growth in in-vitro systems. Keren G; Keysary A; Goldwasser R; Rubinstein E J Antimicrob Chemother; 1994 Jun; 33(6):1253-5. PubMed ID: 7928822 [No Abstract] [Full Text] [Related]
20. Shell-vial assay: evaluation of a new technique for determining antibiotic susceptibility, tested in 13 isolates of Coxiella burnetii. Raoult D; Torres H; Drancourt M Antimicrob Agents Chemother; 1991 Oct; 35(10):2070-7. PubMed ID: 1759829 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]